GSK vs. AZN, HLN, SN, CTEC, HIK, HCM, INDV, GNS, SPI, and ONT
Should you be buying GSK stock or one of its competitors? The main competitors of GSK include AstraZeneca (AZN), Haleon (HLN), Smith & Nephew (SN), ConvaTec Group (CTEC), Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Indivior (INDV), Genus (GNS), Spire Healthcare Group (SPI), and Oxford Nanopore Technologies (ONT). These companies are all part of the "medical" sector.
GSK (LON:GSK) and AstraZeneca (LON:AZN) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations and profitability.
AstraZeneca received 769 more outperform votes than GSK when rated by MarketBeat users. Likewise, 63.61% of users gave AstraZeneca an outperform vote while only 50.21% of users gave GSK an outperform vote.
GSK pays an annual dividend of GBX 64 per share and has a dividend yield of 3.9%. AstraZeneca pays an annual dividend of GBX 228 per share and has a dividend yield of 1.9%. GSK pays out 5,333.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AstraZeneca pays out 7,524.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.
GSK currently has a consensus target price of GBX 1,630.63, suggesting a potential downside of 0.69%. AstraZeneca has a consensus target price of £116.86, suggesting a potential downside of 2.64%. Given GSK's higher probable upside, equities analysts plainly believe GSK is more favorable than AstraZeneca.
AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.
GSK has a net margin of 16.25% compared to AstraZeneca's net margin of 13.00%. GSK's return on equity of 46.38% beat AstraZeneca's return on equity.
GSK has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Comparatively, AstraZeneca has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500.
45.4% of GSK shares are owned by institutional investors. Comparatively, 50.8% of AstraZeneca shares are owned by institutional investors. 1.7% of GSK shares are owned by insiders. Comparatively, 0.2% of AstraZeneca shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, GSK had 1 more articles in the media than AstraZeneca. MarketBeat recorded 5 mentions for GSK and 4 mentions for AstraZeneca. AstraZeneca's average media sentiment score of 0.42 beat GSK's score of 0.05 indicating that AstraZeneca is being referred to more favorably in the news media.
Summary
AstraZeneca beats GSK on 11 of the 20 factors compared between the two stocks.
Get GSK News Delivered to You Automatically
Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GSK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
